Newsletter

Stay up to date on all things colon cancer. Sign up and we’ll send you the latest news, resources, scientific breakthroughs, events, tips, and much more.

Green Tea and Milk Thistle to Colorectal Cancer Patients

November 21, 2019

Overview

Colorectal cancer is the third most common form of cancer found in the United States, and surgical resection (removal) provides the best chance for cure. Unfortunately,  tumor recurrences develop in 30-40% of patients, and there is evidence suggesting that tumor growth is stimulated after surgery for a period of time. This study focuses on the oral administration of a green tea extract and a milk thistle extract during the week immediately before and weeks after surgery. The goal is that the combination of these two extracts should help to inhibit cancer growth in the days leading up to and following surgery.

 

Study Information

This clinical trial will have an estimated enrollment of 30 participants. The primary purpose is treatment. The study began in July 2011 and aims to be completed by November 2020.

 

Inclusion Criteria

 

  • Patients must be age 18 to 85 years
  • Patient must have biopsy proven colon or rectal cancer
  • Cancer should be judged to be stage 1 to 3 based on preoperative staging
  • Patients may be any race and any gender

 

Exclusion Criteria

 

  • Patients with cancer judged to be stage 4 are not eligible
  • Patients undergoing emergency surgery for cancer are not eligible
  • Patients who are immunosuppressed or taking immunosuppressive medications (steroids or chemotherapeutic agents) are not eligible
  • Patients with Crohn’s disease or ulcerative colitis are not eligible
  • Patients with other malignancies are not eligible
  • Patients who are taking part in other neoadjuvant and early adjuvant chemotherapy trials are not eligible

 

Location

This study is taking place at Mount Sinai St. Luke’s Roosevelt Hospital Center, New York, New York, United States, 10019. For further information, please contact Richard L Whelan, MD on (212) 523-8172 or at rwhelan@chpnet.org.

Sponsors/Collaborators

This study is sponsored by Richard Whelan and St. Luke’s-Roosevelt Hospital Center. Richard L Whelan, MD is the Principal Investigator.

Clinical Trials

View All Clinical Trials

DC Vaccine in Colorectal Cancer

This study is assessing the safety, tolerability and immune response rate the of mDC3 vaccine in patients with colorectal cancer.

Diet Modulation of Bacterial Sulfur and Bile Acid Metabolism and Colon Cancer Risk

This diet-intervention trial focuses on African American subjects who are at higher risk for developing colorectal cancer (CRC). Two diets, one…

Participatory Research to Advance Colon Cancer Prevention

The goal of this study is to test strategies to raise rates of colorectal cancer screening among the Latino population. This study will be split…

Reducing Rural Colon Cancer Disparities

This study is exploring the difference in outcomes for cancer patients in rural vs. urban areas. Southern Illinois will be used as the prime…

Young-Onset Microsatellite-Stable Colorectal Cancer

The goal of this laboratory research study is to learn more about genetic factors that may influence the risk for developing colorectal cancer at a…

PalloV-CC in Colon Cancer

This study is looking at the effects of the PalloV CC vaccination on patients with colon cancer. The primary goals are to understand the safety of…

Exercise And Colon Cancer Treatment

This study is looking at how exercise may prevent the recurrence of colon cancer in patients who have completed their treatment. The primary…

Niclosamide in Patients With Resectable Colon Cancer

This study is examining the safety of the drug Niclosamide in patients with colon cancer that are undergoing primary resection (cutting out) of…

Make a comment and share this article on your profile.

Write a comment for your publication

Successfully Shared!

View on my Profile

Send this to a friend